About Us

Douglas Thomson

Chief Executive Officer

Douglas Thomson is Chief Executive Officer and co-founder at Pneumagen. His background is in infectious disease vaccine research and development. He was previously at SingVax, in Singapore, as CEO, and Microscience Ltd as Business Development Director.  Douglas currently sits on the board of Omideon, a St. Andrews based biotech company focused on the development of novel treatments for cancer; he is a non-executive director of EnteroBiotix, a microbiome therapeutics platform and product company and is a Venture Partner with the KAMRA fund, which is focused on infectious disease.

James Noble

Non-Executive Chairman

James joined Pneumagen as Non-Executive Chairman of the Board in 2023. James has over 30 years of industry experience across both public and private biotech and healthcare companies. He is also Chairman at Orexo AB, Sutura Therapeutics and Ingenox, previously Celleron Therapeutics and Non-Executive Director of Lava Therapeutics N.V. James has held non-executive roles at several prominent biotech companies including MediGene AG, PowderJect, Oxford GlycoSciences, CuraGen, Advanced Medical Solutions and GW Pharmaceuticals.

In 2008, James founded Adaptimmune, a Nasdaq listed T-cell therapy company, where he worked as Chief Executive Officer until 2019. Prior to this, James worked as Chief Executive Officer of Immunocore, which he also co-founded. Mr. Noble qualified as a chartered accountant with Price Waterhouse and holds an M.A. degree from the University of Oxford.

Mark R. Bamforth

Non-executive Director

Mark Bamforth is a Non-Executive Director at Pneumagen.

Mark has founded, grown and sold three contract development and manufacturing organizations (CDMOs): Arranta Bio (acquired by Recipharm in 2022), Brammer Bio (acquired by Thermo Fisher Scientific in 2019) and Gallus BioPharmaceuticals (acquired by DPx Holdings in 2014). He was previously at Genzyme Corp. for 22 years, where he latterly led global manufacturing operations.

Mark is an active investor in the healthcare and life sciences sector, serving as a General Partner in the Kineticos AMR Fund I. He currently serves on the boards of Continuus Pharma, Enterobiotix, Entrepreneurial Scotland Foundation, Inceptor Bio, and Pneumagen. He previously sat on multiple CDMO, biotech and trade association boards.

Mark holds an MBA from Henley Management College and a BS in Chemical Engineering from Strathclyde University.

Dr John Beadle

Non-executive Director

John Beadle is a Non-Executive Director at Pneumagen. During his career, John has formed and led several innovative advanced therapy biotech companies through spin-outs, fundraising and acquisitions. Most recently, he co-founded InnDura therapeutics, a Boston, Massachusetts based NK cell therapy company where he is Chairman. Previously, John co-founded PowderMed, a DNA vaccine company, and PsiOxus (now Akamis), a clinical stage cancer gene therapy company. He served as CEO and Board Director of PsiOxus for over 12 years and as Chief Medical Officer and Board Director of PowderMed through to the successful acquisition by Pfizer.

His background is medical, holding roles of increasing seniority in clinical development and medical operations at GSK. At GSK, John managed international teams, oversaw merger and post-integration operations, and led R&D and clinical development processes.

John holds an MD from the University of Witwatersand, and an MBA from the London Business School.

Thomas Engelen

Non-executive Director

Thomas Engelen has a track record in creating value in listed and in Private Equity backed investments in Life Sciences and Chemicals including financial and operational turn-around as part of MBOs and MBIs.

Engelen is co-founder of Pneumagen. As non-exec chair Engelen was part of the team in the successful IPO of GT Biologics Ltd to become 4D Pharma Plc, and of Quantum Specials Ltd to become Quantum Pharma Plc, and remained after the IPOs on their board as non-executive director.

Previous non-executive chair roles were with Akros Chemicals Ltd, Colonis Pharma Ltd, Martindale Pharma Ltd and Stan Chem International Ltd.

Prior to this Engelen worked for Akzo Nobel Pharma in the USA, Brazil, the UK and the Middle East for 19 years in Regional line- and Global HQ management roles.

Current engagements include non – exec chair at TMC Pharma Services Ltd, a global pharmaceutical development organisation specialised in Rare and Orphan diseases, Omideon Ltd, and Innovatrain AG, Switzerland.

Professor Garry Taylor

Director and Chairman of the Scientific Advisory Board

Garry Taylor is a Non-Executive Director and Chair of the Scientific Advisory Board at Pneumagen. Garry is a co-inventor of the CBM intellectual property: the ‘Taylor’ lab has a long history in studying the molecular mechanisms of proteins from respiratory pathogens and it is the work of his team that led to the CBM technology and products. Garry is a co-founder, shareholder, director and advisor to the Company.

Garry was Master and Deputy Principal of the University of St Andrews from 2014-19, holds an Emeritus Professorship and Chairs Pneumagen’s Scientific Advisory Board.